Prognostic prediction for newly diagnosed patients with idiopathic interstitial pneumonia: JIPS Registry (NEJ030)
- PMID: 40101437
- DOI: 10.1016/j.resinv.2025.02.009
Prognostic prediction for newly diagnosed patients with idiopathic interstitial pneumonia: JIPS Registry (NEJ030)
Abstract
Background: Prognostic factors in patients with newly diagnosed idiopathic interstitial pneumonia (IIP) have rarely been analyzed using prospective data. This study investigated prognostic factors in patients with IIP.
Methods: Central interstitial lung disease (ILD) experts established the diagnoses for fibrotic ILD. Prognostic factors using baseline data, including the pathological confidence level of usual interstitial pneumonia (UIP) assessed on a 0%-100% linear analog scale by high-resolution CT (HRCT), pulmonary function tests, and patient-reported outcomes were investigated.
Results: Overall, 866 eligible patients were registered. Patients with unclassifiable idiopathic interstitial pneumonia (n = 272) survived longer than those with idiopathic pulmonary fibrosis (IPF) (n = 469) (hazard ratio [HR] = 0.67; [95% confidence interval [CI]: 0.47-0.95]; P = 0.022); however, IPF as IIPs classification was not a significant prognostic factor at diagnosis (P = 0.577). UIP pattern on HRCT, age, body mass index, forced vital capacity, diffusing capacity of the lungs for carbon monoxide, and St. George's Respiratory Questionnaire were risk factors for survival (P < 0.05). Patients with proposed progressive pulmonary fibrosis (PPF) had poorer prognoses than those without proposed PPF (HR = 5.63; [95% CI: 3.17-10.00]; P < 0.001). Patients with progressive fibrosing ILD (PF-ILD) had poorer prognoses than those without PF-ILD (HR = 7.85; [95% CI: 3.38-18.3]; P < 0.001).
Conclusions: A prospective registry of patients with newly diagnosed IIP provided evidence that the UIP pattern on HRCT by analog scale was a prognostic predictor. Proposed PPF and PF-ILD were valuable for discriminating prognosis. (JIPS Registry, ClinTrials.gov, NCT03041623).
Keywords: Idiopathic pulmonary fibrosis; Interstitial lung disease; Progressive fibrosing interstitial lung disease; Progressive pulmonary fibrosis; Usual interstitial pneumonia.
Copyright © 2025 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest T. Ogura has received honoraria from Nippon Boehringer Ingelheim Co., Ltd. S. Hisata has received honoraria from Nippon Boehringer Ingelheim Co., Ltd. T. Baba has received honoraria from Nippon Boehringer Ingelheim Co., Ltd. Y. Kondoh has received honoraria from Nippon Boehringer Ingelheim Co., Ltd. T. Suda has received honoraria and research funding from Nippon Boehringer Ingelheim Co., Ltd. and AstraZeneca K.K. T. Johkoh has received honoraria from Nippon Boehringer Ingelheim Co., Ltd., AstraZeneca K.K., and Kyorin Pharmaceutical Co., Ltd. T. Iwasawa has received research funding from Canon Medical systems Corp. H. Tomioka has received honoraria from Nippon Boehringer Ingelheim Co., Ltd. M. Bando has received honoraria from Nippon Boehringer Ingelheim Co., Ltd. A. Azuma has received honoraria, travel fees, gifts, and others from Nippon Boehringer Ingelheim Co., Ltd. Y. Inoue has received honoraria from Nippon Boehringer Ingelheim Co., Ltd. N. Ishikawa has received honoraria from Nippon Boehringer Ingelheim Co., Ltd. Y. Nakamura has received honoraria from Nippon Boehringer Ingelheim Co., Ltd. A. Miyamoto has received honoraria from Nippon Boehringer Ingelheim Co., Ltd. K. Tomii has received honoraria from Nippon Boehringer Ingelheim Co., Ltd., Teijin Pharma Ltd., and Teijin Healthcare. Y. Miyazaki has received honoraria, research funding, subsidies, and donations from Nippon Boehringer Ingelheim Co., Ltd. H. Chiba has received honoraria from Nippon Boehringer Ingelheim Co., Ltd. H. Ishii has received honoraria from Nippon Boehringer Ingelheim Co., Ltd., AstraZeneca K.K., KYORIN Pharmaceutical Co., Ltd., and GlaxoSmithKline K.K. N. Hamada has received research funding from Nippon Boehringer Ingelheim Co., Ltd. J. Fukuoka has stocks of Pathology Institute Corp., and N Lab. J. Fukuoka also has received manuscript fees from Ibex. K. Fujimoto has received research funding from Mikron K.K. T. Suzuki has received honoraria from Nippon Boehringer Ingelheim Co., Ltd., and AstraZeneca K.K. Y. Nishioka has received honoraria from Nippon Boehringer Ingelheim Co., Ltd. N. Hattori has received honoraria from Nippon Boehringer Ingelheim Co., Ltd., and Shionogi & Co., Ltd. H. Miyata has received research funding from National Clinical Database. K. Hagiwara has received advisory board fees, patent royalties, and licensing fees from Eiken Chemical Co., Ltd., and LSI Medience. K. Hagiwara also has received honoraria, research funding, subsidies, and donations from Eiken Chemical Co., Ltd., AstraZeneca K.K., Chugai pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., and Ono Pharmaceutical Co., Ltd. R. Okuda, N. Arai, T. Takihara, M. Hamaguchi, T. Arai, Y. Terasaki, F. Sakai, R. Egashira, H. Sumikawa, S. Sakamoto, N. Hashimoto, S. Morita, N. Ichihara, K. Kobayashi and T. Nukiwa have no competing interests.
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Medical